糖心视频

We listened to the full arguments and, while predicting an outcome is always difficult, our overall impression is that Monsanto had stronger arguments and is more likely than not to prevail; a somewhat subdued bench makes a prediction harder than usual, but on balance, the weight of questioning seemed to suggest that Monsanto had the upper hand.

Separately, Bayer is pursuing a proposed $6.25 bn to $7.25 bn class settlement in Missouri in King v Monsanto designed to capture a broad universe of current and future claimants, though significant execution risks remain, including class certification, opt-out, and appellate risk.

President Trump鈥檚 February 2026 executive order invoking the Defense Production Act to protect domestic glyphosate supply adds a third leg to Bayer鈥檚 liability-management strategy, though its practical legal effect on pending civil claims remains limited and uncertain.

Taken together, a SCOTUS victory, a successful class settlement, and favorable executive branch action would constitute a formidable 鈥�1-2-3 punch鈥� that, if it succeeds, would allow Bayer/Monsanto to manage one of the largest mass tort overhangs in recent corporate history without resort to bankruptcy, including the controversial Texas two-step maneuver that is itself under mounting pressure in the courts and in Congress.